

Product Data Sheet

Product Name: TNIK-IN-3

Cat. No.: GC65328

Chemical Properties

Cas. No. 2754265-25-1


Formula C₂₃H₁₈FN₃O₂ M.Wt 387.41

Solubility DMSO : 83.33 mg/mL (215.10 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

TNIK-IN-3 is a potent, selective and orally active inhibitor of Traf2- and Nck-interacting protein kinase (TNIK), with an IC₅₀ of 0.026 μM. TNIK-IN-3 could also inhibit Flt4 (IC₅₀=0.030 μM), Flt1 (IC₅₀=0.191 μM) and DRAK1 (IC₅₀=0.411 μM). TNIK-IN-3 can be used for the research of colorectal

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

cancer[1].

TNIK-IN-3 (compound 21k) inhibits Aurora-A, GCK, and MLK3 with IC50s of 0.517 μ M, 3.657 μ M, and 4.552 μ M, respectively[1].TNIK-IN-3 (0.1-100 μ M; 3 days) inhibits the viability of HCT116 and DLD-1 cells, with IC50s of 4.26 μ M and 8.00 μ M, respectively[1].TNIK-IN-3 (2.5-40 μ M; 10 days) dose-dependently inhibits the colony formation of HCT116 and DLD-1 cells[1].TNIK-IN-3 (5-20 μ M; 48 h) inhibits the migration of HCT116 and DLD-1 cells[1].TNIK-IN-3 (5-40 μ M; 48 h) dose-dependently inhibits the expression ofLRP5 and LRP6 proteins, Wnt target genes AXIN2 and c-Myc in HCT116 cells[1].TNIK-IN-3 (5-20 μ M; 48 h) significantly suppresses the phosphorylation of JNK1/2 in Hela cells[1].

TNIK-IN-3 (compound 21k) (100-150 mg/kg; p.o. twice daily for 18 days) inhibits tumor growth in a dose-dependent manner[1].

[1]. Li Y, et, al. Discovery of 3,4-Dihydrobenzo[f][1,4]oxazepin-5(2 H)-one Derivatives as a New Class of Selective TNIK Inhibitors and Evaluation of Their Anti-Colorectal Cancer Effects. J Med Chem. 2022 Jan 5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA